For the Inventor, By the Inventor

Enter assignee name

Boulder, CO, United States of America

Miragen Therapeutics, Inc.

USPTO Granted Patents = 20

CIPO Patents = 4

EPO Patents = 6

Trademarks = 1

Forward Citations = 49

Loading Chart...

Loading Chart...

14 inventors (with patents filed for the assignee):

Christina Marie Dalby (16 out of 16 patents)

Rusty L Montgomery (10 out of 10 patents)

Eva Van Rooij (9 out of 23 patents)

4. Anita Seto (7 out of 7 patents)

5. Aimee Jackson (5 out of 5 patents)

6. Corrie Lynn Gallant-Behm (4 out of 4 patents)

7. Kurt Vagle (4 out of 11 patents)

8. William Marshall (3 out of 138 patents)

9. David Rodman (3 out of 3 patents)

10. Xuan Beatty (3 out of 3 patents)

11. Kathryn H Hutnick (3 out of 3 patents)

12. Eric N Olson (1 out of 54 patents)

13. Thomas G Hullinger (1 out of 1 patent)

14. Chad Grueter (1 out of 1 patent)

15. Eva Van Rooij (1 patent)

20 patents: Sort by Forward Citations

1. 10337005 - Oligonucleotide-based inhibitors comprising locked nucleic acid motif (2019-07-02),

2. 10316318 - Oligonucleotide compositions and uses thereof (2019-06-11),

3. 10280422 - MiR-92 inhibitors and uses thereof (2019-05-07),

4. 10144930 - Inhibitors of MYH7B and uses thereof (2018-12-04),

5. 10030042 - Synthesis of bicyclic nucleosides (2018-07-24),

6. 10011833 - Bridged bicyclic nucleosides (2018-07-03),

7. 9994852 - Oligonucleotide compositions and uses thereof (2018-06-12),

8. 9994847 - miR-29 mimics and uses thereof (2018-06-12),

9. 9885042 - miR-92 inhibitors and uses thereof (2018-02-06),

10. 9803202 - Oligonucleotide-based inhibitors comprising locked nucleic acid motif (2017-10-31),

11. 9771585 - miR-155 inhibitors for treating cutaneous T cell lymphoma (CTCL) (2017-09-26),

12. 9752144 - Inhibitors of MYH7B and uses thereof (2017-09-05),

13. 9752143 - Locked nucleic acid inhibitor of miR-145 and uses thereof (2017-09-05),

14. 9428749 - Control of whole body energy homeostasis by microRNA regulation (2016-08-30),

15. 9416360 - Base modified oligonucleotides (2016-08-16),

Miragen Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of innovative microRNA-based therapeutics for various diseases. Their expertise lies in the discovery and development of microRNA-targeted therapies, which have the potential to address unmet medical needs. Miragen Therapeutics is dedicated to advancing their pipeline through rigorous research and clinical studies, aiming to improve patient outcomes and quality of life.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

20 Patents

#56 in Boulder, CO

#310 in Colorado

#15,887 in US

#30,353 in the World

Boulder, CO, United States of America

Miragen Therapeutics, Inc.

Forward Citations = 49

14 inventors:

Christina Marie Dalby (16 out of 16 patents)

Rusty L Montgomery (10 out of 10 patents)

Eva Van Rooij (9 out of 23 patents)

4. Anita Seto (7 out of 7 patents)

5. Aimee Jackson (5 out of 5 patents)

Please report any incorrect information to support@idiyas.com

Loading…